核酸适体偶联药物的生物偶联构建技术与应用

核酸适体被称为“化学抗体”, 具有与抗体类似或更加优异的特异性和亲和力, 可以精准地靶向靶蛋白, 与靶蛋白特异性结合. 此外, 核酸适体还具有获取简单、 合成简便、 易于进行化学修饰、 不易变性、 靶标范围广、 免疫原性低及细胞内化快等优点, 已被广泛应用于众多研究领域. 在癌症治疗领域, 核酸适体作为一种优异的靶向识别工具和药物递送载体, 可实现抗肿瘤药物的精准递送. 将核酸适体与药物分子偶联, 可通过核酸适体的靶向作用使药物分子随核酸适体共同进入靶细胞, 实现药物分子在靶细胞内的富集, 进而促进靶细胞的死亡. 近年来, 核酸适体偶联药物已成为癌症靶向治疗的前沿新兴领域, 希望通过该领域的深入研究为癌症靶向治疗领域提供新思路. 本文综合评述了以生物偶联技术构建的核酸适体偶联药物及其应用研究.     

核酸适体-纳米材料复合物用于癌症的诊断与靶向治疗研究进展

因具有独特的光、电、磁、热等优异性能,纳米材料已被广泛应用于生物分析与生物医学领域。核酸适体是一类能够高亲和力和高特异性地与靶标结合的寡核苷酸序列。将核酸适体作为识别单元与纳米材料相结合,可以构建核酸适体-纳米材料复合物。近年来,在肿瘤靶向治疗方面,核酸适体-纳米材料复合物受到了人们的广泛关注。通过纳米材料与具有特异性识别能力的核酸适体的结合,核酸适体-纳米材料复合物可以为癌症治疗提供一种更有效的、低毒副作用的新策略。本文综述了核酸适体-纳米材料复合物作为药物输送载体在癌症的特异性识别与诊断及靶向治疗方面的应用。除此之外,本文还总结了核酸适体-纳米材料复合物与其他新兴技术的有效结合从而提高选择性和癌症治疗效率的相关研究进展。     

化学修饰提高核酸适体结合亲和力的研究进展

核酸适体(Aptamer)是通过体外筛选得到的短单链DNA或RNA寡核苷酸, 具有与抗体相当或更优异的特异性及亲和力, 且具有靶标范围广、 易制备和灵活可控修饰、 免疫原性低、 批次差异性小以及易于运输保存等优势, 为食品、 环境和生物医学等领域提供了全新的分子识别工具, 获得了研究者的广泛关注. 但是目前其商业应用的数量仍有限. 为了增强核酸适体的应用性能, 研究者对核酸适体进行了大量的改性研究. 本文系统总结了核酸适体筛选前、 后采用非共价或共价方式对其进行化学修饰, 以增加核酸适体与靶标的结合亲和力的相关研究进展, 并对未来发展前景进行了展望.     

功能化核酸适体的筛选及分子识别应用

核酸适体是从寡核苷酸文库中筛选获得的一段单链寡核苷酸. 由于能与多种靶标分子高特异性结合, 核酸适体已发展成为一种新兴的分子识别工具, 广泛应用于生物医学等领域. 天然核酸文库有限的化学组成限制了核酸适体的结构和功能, 进而限制了其在分子识别中的应用. 功能化核酸适体通过引入特定的化学官能团使核酸序列具有更丰富的构象和功能, 增强其分子识别能力. 然而, 功能化核酸很难与核酸扩增方法兼容, 因而难以使用传统筛选方法进行功能化核酸的筛选. 因此, 优化筛选方法对于获得具有优异性能的功能化核酸适体至关重要. 本综述总结了功能化核酸适体的筛选方法, 并介绍了其作为分子识别工具在生物医学领域中的应用.     

核酸适体在生物医学中的应用*

核酸适体是经配体指数富集系统进化技术（SELEX）筛选获得的一类能够特异性地结合离子、分子,甚至整个细胞的单链DNA或者RNA分子。本文介绍了核酸适体及相关筛选技术SELEX;综述了近年来以提高筛选效率和效果为目标的核酸适体筛选技术新进展;列举了核酸适体在无机离子、小分子、生物大分子和肿瘤细胞检测、肿瘤标记物的发现等方面的应用;讨论了基于核酸适体的靶向治疗策略;最后对核酸适体在生物医学上的应用前景进行了展望。     

核酸适体靶向的膜蛋白识别与功能调控研究进展

膜蛋白在细胞生命活动中发挥着重要作用, 研究并调控细胞膜蛋白的结构和功能有助于阐明生命活动的基本规律, 为新型药物研发和高效疾病诊治提供研究基础. 核酸适体是一类特殊的寡核苷酸序列, 因具有特异性识别靶标的能力而被广泛用于生物传感领域. 将核酸适体与DNA纳米技术相结合, 利用DNA分子可程序化设计、 可功能化修饰等优势, 发展核酸适体靶向的膜蛋白识别与功能调控方法可为研究膜蛋白相互作用提供有力工具. 本文介绍了基于核酸适体靶向识别的DNA纳米技术在膜蛋白识别及细胞功能调控中的研究进展, 并对核酸适体靶向的膜蛋白识别及功能调控领域面临的挑战进行了分析, 对其应用前景进行了展望.     

核酸适体功能化的二维材料场效应晶体管传感器研究进展

二维材料场效应晶体管传感器具有可调的电学性质和高的灵敏度, 非常适合用于构建高性能的传感器, 应用于疾病诊断和环境监测等领域. 核酸适体是一种生物识别分子, 具有特异性强、 稳定性高等优势. 近年来, 核酸适体功能化的二维材料场效应晶体管传感器在医疗诊断和环境监测等领域取得了显著的研究进展. 本文综合评述了核酸适体功能化的二维材料场效应晶体管传感器的最新研究进展, 对场效应晶体管传感器的结构及传感原理进行了概括, 详细介绍了二维材料的制备方法以及核酸适体功能化器件的设计原理. 在此基础上, 对核酸适体功能化的二维材料场效应晶体管传感器在疾病诊断和环境监测领域的应用进展进行了概述, 讨论了核酸适体功能化的二维材料场效应晶体管传感器面临的一些问题和挑战, 对其发展前景进行了展望.     

基于核酸适体检测ATP的酶联分析新方法

基于核酸适体对靶标的特异性识别和辣根过氧化物酶(HRP)的高效催化反应, 发展了一种用于检测三磷酸腺苷(ATP)的酶联核酸适体分析新方法. 核酸适体和靶标的特异性结合导致与核酸适体杂交的短链DNA解链, 解离的DNA通过杂交被固定在另一酶标板的DNA捕获. 解离的DNA预先标记了异硫氰酸荧光素(FITC)基团, FITC特异性结合HRP标记的FITC抗体, HRP作为信号传导元素催化四甲基二苯胺(TMB)底物显色, 通过颜色变化及450 nm波长处吸光度的变化检测ATP. 该方法对ATP具有良好的选择性, 检测不受其它物质如GTP, UTP和CTP的干扰, 且检测能在较复杂的试样(体积分数10%和50%的血清)中进行. 实验结果表明, 在ATP浓度为50~400 nmol/L范围内, 具有良好的线性关系, 检出限为26 nmol/L.     

适配体在癌症诊断与靶向治疗中的研究进展

核酸适配体是利用体外筛选技术,即指数富集的配体系统进化技术(SELEX),从核酸分子文库中得到的寡核苷酸片段。其与靶标物有很高的特异性和亲和力,将适配体作为识别单元的生物传感研究以及适配体偶联成像试剂的生物体内外成像研究在临床诊断中有很大的应用前景,此外,适配体靶向癌细胞或组织的治疗方法相比传统化学治疗副作用更小,在临床上也有极大的应用前景。本文综述了适配体目前在癌症诊断和靶向治疗两个方面的研究进展,并分析现阶段存在的问题以及面临的挑战。     

基于核酸适体的丙肝病毒核心蛋白检测新方法

丙型病毒性肝炎是由丙型肝炎病毒(hepatitis C virus,HCV)引起的一种传染性疾病.发展对HCV抗原具有高亲和力高特异性的识别分子和检测方法对丙肝进行早期诊断具有非常重要的意义.我们通过SELEX筛选得到了能特异性识别HCV核心蛋白(core蛋白)的DNA核酸适体,建立了可对HCV core蛋白进行高灵敏检测的核酸适体-酶联免疫新方法,并成功应用于丙肝病人血清中HCV core蛋白的检测,有望发展成为简便、灵敏、低成本的HCV早期诊断和血清筛查新方法.     

核酸适配体在癌症诊断中的研究进展

核酸适配体是通过指数富集配体系统进化技术(SELEX)从体外合成的寡核苷酸文库中筛选得到的短的寡核苷酸分子(ssDNA或RNA).核酸适配体能够通过折叠成特定的空间结构与靶标分子进行特异性结合,与抗体相比,适配体具有高亲和力、易修饰、低成本、易于合成和低免疫原性等优势,可以针对细胞、蛋白质、组织、生长因子进行癌症生物标...     

Aptamer–nanoparticle complexes as powerful diagnostic and therapeutic tools

Correct diagnosis and successful therapy are extremely important to enjoy a healthy life when suffering from a disease. To achieve these aims, various cutting-edge technologies have been designed and fabricated to diagnose and treat specific diseases. Among these technologies, aptamer–nanomaterial hybrids have received considerable attention from scientists and doctors because they have numerous advantages over other methods, such as good biocompatibility, low immunogenicity and controllable selectivity. In particular, aptamers, oligonucleic acids or peptides that bind to a specific target molecule, are regarded as outstanding biomolecules. In this review, several screening techniques for aptamers, also called systematic evolution of ligands by exponential enrichment (SELEX) methods, are introduced, and diagnostic and therapeutic aptamer applications are also presented. Furthermore, we describe diverse aptamer–nanomaterial conjugate designs and their applications for diagnosis and therapy.     

Cell-SELEX-based aptamer-conjugated nanomaterials for enhanced targeting of cancer cells

Early detection and treatment of cancer depends on developing highly sensitive and specific methods for targeting cancer cells. To do this, aptamers, which are generated by a novel technique called cell-SELEX (systematic evolution of ligands by exponential enrichment), have been widely applied in cancer cell targeting based on such merits as high target affinity and specificity, small size, minimal immunogenicity, and ease of chemical modification. Furthermore, aptamers can gain more flexibility as cancer c...     

A general approach for rational design of fluorescent DNA aptazyme sensors based on target-induced unfolding of DNA hairpins

DNA aptazymes are allosteric DNAzymes activated by the targets of DNA aptamers. They take the advantages of both aptamers and DNAzymes, which can recognize specific targets with high selectivity and catalyze multiple-turnover reactions for signal amplification, respectively, and have shown their great promise in many analytical applications. So far, however, the available examples of DNA aptazyme sensors are still limited in utilizing only several DNAzymes and DNA aptamers, most likely due to the lack of a general and simple approach for rational design. Herein, we have developed such a general approach for designing fluorescent DNA aptazyme sensors. In this approach, aptamers and DNAzymes are connected at the ends to avoid any change in their original sequences, therefore enabling the general use of different aptamers and DNAzymes in the design. Upon activation of the aptazymes by the targets of interest, the rate of fluorescence enhancement via the cleavage of a dually labeled substrate by the active aptazymes is then monitored for target quantification. Two DNAzymes and two aptamers are used as examples for the design of three fluorescent aptazyme sensors, and they all show high selectivity and sensitivity for the detection of their targets. More DNA aptazyme sensors for a broader range of targets could be developed by this general approach as long as suitable DNAzymes and aptamers are used.     

The aptamers generated from HepG2 cells

Liver cancer, as the second cause of cancer death all around the world, resulted in a series of chronic liver diseases. More than 80%of the patients cannot receive effective treatment because of their advanced disease or poor liver function. It is time to improve early clinical diagnosis and find optimal therapeutic treatments. As the tumor cells behave differently from the cell-surface molecules, it is necessary to find a highly specific probe. The aptamers, known as "chemical antibodies", can bind to their target molecules with high affinity and high specificity. The apatmers were obtained by Cell-SELEX, which was aimed at finding the aptamers against whole living cells. In the article, after 19 selections, the ssDNA pool was cloned and sequenced. After that, six aptamers were obtained, named apt_A to apt_F. By incubating the aptamers with different cells, except apt_E, the other aptamers showed high specificity. As for apt_E, which showed high affinity to several cancer cells, was a potential probe for the common protein presented by several different cancer cells. The equilibrium dissociation constants(Kd) were evaluated by measuring the flow cytometry signal that characterized the binding ability of aptamers to the target cells at a series of concentrations ranging from 46.3(4.5) nM to 199.4(44.2) nM, which exposed the high binding affinities of these aptamers. The research in the confocal fluorescence images further confirmed the specificity of these aptamers and the fact that the aptamers were combined with the targets on the cell-surface.     

胃腺癌核酸适配体的筛选与特异性研究

核酸适配体可作为分子探针应用于胃腺癌的早期诊断和治疗,具有广泛应用前景。本实验利用Serum-SELEX（Ser-SELEX）技术筛选胃腺癌核酸适配体。通过对候选适配体二级结构分析,其二级结构多为茎环结构。圆二色谱分析显示,7条候选核酸适配体呈右手螺旋特征。通过荧光定量核酸扩增检测系统（q-PCR）检测了候选核酸适配体对胃腺癌靶标的亲和力,表明候选核酸适配体浓度梯度与Ct值均呈正相关,亲和力常数为纳摩尔级别。利用q-PCR法、量子点法验证了候选核酸适配体识别靶标的特异性,结果均显示Apt-101对靶标亲和力更高,特异性更强,Apt-101的平衡解离常数（K_d值）为6.444±1.128nmol/L,特异性检测阳性率大于70%。     

Recent Progress in Aptamer‐Based Functional Probes for Bioanalysis and Biomedicine

Nucleic acid aptamers are short synthetic DNA or RNA sequences that can bind to a wide range of targets with high affinity and specificity. In recent years, aptamers have attracted increasing research interest due to their unique features of high binding affinity and specificity, small size, excellent chemical stability, easy chemical synthesis, facile modification, and minimal immunogenicity. These properties make aptamers ideal recognition ligands for bioanalysis, disease diagnosis, and cancer therapy. This review highlights the recent progress in aptamer selection and the latest applications of aptamer‐based functional probes in the fields of bioanalysis and biomedicine.     

Selection of DNA Aptamers with Affinity for Pro-gastrin-Releasing Peptide (proGRP), a Tumor Marker for Small Cell Lung Cancer

Aptamers are single-strand oligonucleotides that are generated by the systemic evolution of ligands by exponential enrichment (SELEX) technique and that can bind to target molecules specifically. However, only a few aptamers have been developed to date against tumor markers. To utilize aptamers for tumor diagnosis, a variety of aptamers are required. Here, a single-stranded DNA aptamer specific for pro-gastrin-releasing peptide (proGRP), a marker for small cell lung cancer, was selected using SELEX. After selection, identical sequences were found in the DNA library. This sequence was selected and its binding affinity to proGRP was evaluated using surface plasmon resonance.